Coiled Therapeutics

Coiled Therapeutics is a biotechnology company specializing in the development of small molecule inhibitors designed to disrupt protein-protein interactions mediated by coiled-coil domains. The company's lead research program targets STAT3, a transcription factor that is frequently overactivated in human cancers and is associated with poor prognosis and resistance to therapy. Unlike traditional approaches that target the SH2 domain of STAT3, Coiled Therapeutics focuses on the coiled-coil domain to prevent protein dimerization and subsequent nuclear entry. This novel mechanism of action aims to provide a more selective therapeutic window for treating solid tumors and inflammatory disorders. The company's foundation is built upon structural biology and translational research originating from Tel Aviv University.